CRL Cash & equivalents
Cash & equivalents at Charles River Laboratories rose to $214M in fiscal 2025, from $195M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 1100682 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$214M
FY2024 $195M
HIGH$277M FY2023
LOW$195M FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $214M | +$19M |
| FY2024 | $195M | $-82M |
| FY2023 | $277M | +$43M |
| FY2022 | $234M | $-7M |
| FY2021 | $241M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · CRL company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.